LakeShore Biopharma Co., Ltd.

LakeShore Biopharma Co., Ltd. (ticker: LSBCF) is an OTC-listed pharmaceutical preparations company. DredgeCap's structured extraction of LSBCF's SEC filings surfaces 3 active risk signals, including 1 auditor-change signal, 1 delisting/deregistration signal, and 1 late-filing signal. LSBCF reported $85.67M in revenue and -$13.93M for the period ending 2025-03-31, with operating cash flow of -$16.85M. Cash and equivalents stood at $3.91M (down 88.7% year-over-year). Total assets of $190.53M exceed total liabilities of $120.91M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

LSBCF Cash Runway

Months-of-runway analysis for LSBCF, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on LSBCF

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.